Cargando…
MET inhibition enhances PARP inhibitor efficacy in castration‐resistant prostate cancer by suppressing the ATM/ATR and PI3K/AKT pathways
Up to 30% of patients with metastatic castration‐resistant prostate cancer (CRPC) patients carry altered DNA damage response genes, enabling the use of poly adenosine diphosphate–ribose polymerase (PARP) inhibitors in advanced CRPC. The proto‐oncogene mesenchymal–epithelial transition (MET) is cruci...
Autores principales: | Zhou, Sihai, Dai, Zhihong, Wang, Liang, Gao, Xiang, Yang, Liqin, Wang, Zhenwei, Wang, Qi, Liu, Zhiyu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650038/ https://www.ncbi.nlm.nih.gov/pubmed/34761497 http://dx.doi.org/10.1111/jcmm.17037 |
Ejemplares similares
-
Targeting c-MET to Enhance the Efficacy of Olaparib in Prostate Cancer
por: Wang, Zhenwei, et al.
Publicado: (2021) -
Cancer Cells Haploinsufficient for ATM Are Sensitized to PARP Inhibitors by MET Inhibition
por: D’Ambrosio, Concetta, et al.
Publicado: (2022) -
Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells
por: Lloyd, Rebecca L., et al.
Publicado: (2020) -
Differential responses to taxanes and PARP inhibitors in ATM‐ versus BRCA2‐mutated metastatic castrate‐resistant prostate cancer
por: Su, Christopher T., et al.
Publicado: (2022) -
Functional analyses of ATM, ATR and Fanconi anemia proteins in lung carcinoma: ATM, ATR and FA in lung carcinoma
por: Beumer, Jan H., et al.
Publicado: (2015)